Pharma & Healthcare
Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
- Aug 11, 25
- ID: 436821
- Pages: 91
- Figures: 98
- Views: 2
The global Benign Prostatic Hyperplasia (BPH) Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
By Type: (Dominant Segment vs High-Margin Innovation)
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospitals
Drugstores
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Eli Lilly in Europe)
- Emerging Product Trends: Alpha-Blocker adoption vs. Phosphodiesterase Type-5 Inhibitors premiumization
- Demand-Side Dynamics: Hospitals growth in China vs. Drugstores potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Benign Prostatic Hyperplasia (BPH) Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Phosphodiesterase Type-5 Inhibitors in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Drugstores in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Alpha-Blocker dominance in Europe vs. Phosphodiesterase Type-5 Inhibitors demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Market Segmentation
By Company:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
By Type: (Dominant Segment vs High-Margin Innovation)
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospitals
Drugstores
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Eli Lilly in Europe)
- Emerging Product Trends: Alpha-Blocker adoption vs. Phosphodiesterase Type-5 Inhibitors premiumization
- Demand-Side Dynamics: Hospitals growth in China vs. Drugstores potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Benign Prostatic Hyperplasia (BPH) Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Phosphodiesterase Type-5 Inhibitors in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Drugstores in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Alpha-Blocker dominance in Europe vs. Phosphodiesterase Type-5 Inhibitors demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Drugs by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020 & 2024 & 2031)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts (2020-2031)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2025)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Type (2020-2025)
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2025)
3.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2026-2031)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2026-2031)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2026-2031)
3.3 Different Types Benign Prostatic Hyperplasia (BPH) Drugs Representative Players
4 Global Market Size by Application
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Application (2020-2025)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2020-2025)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2026-2031)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2026-2031)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Benign Prostatic Hyperplasia (BPH) Drugs Application
5 Competition Landscape by Players
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2020-2025)
5.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Revenue (2020-2025)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2024)
5.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
5.7 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.1.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.1.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.1.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.2.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.2.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.2.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.3.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.3.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.3.4 China Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.4.1.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.4.1.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.4.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.4.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Eli Lilly
7.1.1 Eli Lilly Company Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.1.5 Eli Lilly Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Information
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.2.5 GlaxoSmithKline Recent Development
7.3 Astellas Pharma
7.3.1 Astellas Pharma Company Information
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.3.5 Astellas Pharma Recent Development
7.4 Sanofi
7.4.1 Sanofi Company Information
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.4.5 Sanofi Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.5.5 Pfizer Recent Development
7.6 Abbott
7.6.1 Abbott Company Information
7.6.2 Abbott Business Overview
7.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.6.5 Abbott Recent Development
7.7 Allergan
7.7.1 Allergan Company Information
7.7.2 Allergan Business Overview
7.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.7.5 Allergan Recent Development
7.8 TEVA
7.8.1 TEVA Company Information
7.8.2 TEVA Business Overview
7.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.8.5 TEVA Recent Development
7.9 Mylan
7.9.1 Mylan Company Information
7.9.2 Mylan Business Overview
7.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.9.5 Mylan Recent Development
7.10 Novartis
7.10.1 Novartis Company Information
7.10.2 Novartis Business Overview
7.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.10.5 Novartis Recent Development
7.11 Merck
7.11.1 Merck Company Information
7.11.2 Merck Business Overview
7.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.11.5 Merck Recent Development
8 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
8.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
9.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
10 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
10.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
10.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Scope
1.2 Benign Prostatic Hyperplasia (BPH) Drugs by Type
1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020 & 2024 & 2031)
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Benign Prostatic Hyperplasia (BPH) Drugs by Application
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts (2020-2031)
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2025)
2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
2.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Type (2020-2025)
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2025)
3.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2026-2031)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2026-2031)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2026-2031)
3.3 Different Types Benign Prostatic Hyperplasia (BPH) Drugs Representative Players
4 Global Market Size by Application
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Review by Application (2020-2025)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2025)
4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2020-2025)
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2026-2031)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2026-2031)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Benign Prostatic Hyperplasia (BPH) Drugs Application
5 Competition Landscape by Players
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2020-2025)
5.2 Global Top Benign Prostatic Hyperplasia (BPH) Drugs Players by Revenue (2020-2025)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2024)
5.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
5.7 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.1.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.1.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.1.4 North America Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.2.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.2.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.2.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.2.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.3.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.3.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.3.4 China Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company
6.4.1.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025)
6.4.1.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025)
6.4.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2020-2025)
6.4.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2020-2025)
6.4.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Eli Lilly
7.1.1 Eli Lilly Company Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.1.5 Eli Lilly Recent Development
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Information
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.2.5 GlaxoSmithKline Recent Development
7.3 Astellas Pharma
7.3.1 Astellas Pharma Company Information
7.3.2 Astellas Pharma Business Overview
7.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.3.5 Astellas Pharma Recent Development
7.4 Sanofi
7.4.1 Sanofi Company Information
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.4.5 Sanofi Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.5.5 Pfizer Recent Development
7.6 Abbott
7.6.1 Abbott Company Information
7.6.2 Abbott Business Overview
7.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.6.5 Abbott Recent Development
7.7 Allergan
7.7.1 Allergan Company Information
7.7.2 Allergan Business Overview
7.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.7.5 Allergan Recent Development
7.8 TEVA
7.8.1 TEVA Company Information
7.8.2 TEVA Business Overview
7.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.8.5 TEVA Recent Development
7.9 Mylan
7.9.1 Mylan Company Information
7.9.2 Mylan Business Overview
7.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.9.5 Mylan Recent Development
7.10 Novartis
7.10.1 Novartis Company Information
7.10.2 Novartis Business Overview
7.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.10.5 Novartis Recent Development
7.11 Merck
7.11.1 Merck Company Information
7.11.2 Merck Business Overview
7.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2020-2025)
7.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
7.11.5 Merck Recent Development
8 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
8.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
9.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
10 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
10.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
10.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2020-2025)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2020-2025)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Region (2026-2031)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share Forecast by Region (2026-2031)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (M Units) & (2020-2025)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2020-2025)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (US$/Unit) & (2020-2025)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (M Units) & (2026-2031)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (US$/Unit) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (M Units) & (2020-2025)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2020-2025)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (US$/Unit) & (2020-2025)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (M Units) & (2026-2031)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (US$/Unit) & (2026-2031)
Table 27. New Sources of Growth in Benign Prostatic Hyperplasia (BPH) Drugs Application
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (M Units) & (2020-2025)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2020-2025)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2020-2025)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2024)
Table 33. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (US$/Unit) & (2020-2025)
Table 34. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
Table 36. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 42. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 54. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 56. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 58. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 59. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 60. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 61. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 62. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 63. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 64. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 66. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 67. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 68. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 69. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 70. Eli Lilly Company Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 74. Eli Lilly Recent Development
Table 75. GlaxoSmithKline Company Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 79. GlaxoSmithKline Recent Development
Table 80. Astellas Pharma Company Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 84. Astellas Pharma Recent Development
Table 85. Sanofi Company Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 89. Sanofi Recent Development
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 94. Pfizer Recent Development
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 99. Abbott Recent Development
Table 100. Allergan Company Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 104. Allergan Recent Development
Table 105. TEVA Company Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 109. TEVA Recent Development
Table 110. Mylan Company Information
Table 111. Mylan Description and Business Overview
Table 112. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. Mylan Recent Development
Table 115. Novartis Company Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. Novartis Recent Development
Table 120. Merck Company Information
Table 121. Merck Description and Business Overview
Table 122. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Merck Recent Development
Table 125. Production Base and Market Concentration Rate of Raw Material
Table 126. Key Suppliers of Raw Materials
Table 127. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 128. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 129. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 130. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 131. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2024 & 2031
Figure 4. Alpha-Blocker Product Picture
Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2024 & 2031
Figure 9. Hospitals Examples
Figure 10. Drugstores Examples
Figure 11. Others Examples
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2020-2031) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends Growth Rate (2020-2031) & (US$/Unit)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 17. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2020 VS 2024
Figure 19. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 23. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 25. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2020-2025)
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2026-2031)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2026-2031)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2020-2025)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2026-2031)
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2026-2031)
Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2024)
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2024)
Figure 36. Global 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs: 2020 & 2024
Figure 37. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 39. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 40. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Region (2020-2025)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2020-2025)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2020-2025)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Forecast by Region (2026-2031)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share Forecast by Region (2026-2031)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (M Units) & (2020-2025)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2020-2025)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (US$/Unit) & (2020-2025)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (M Units) & (2026-2031)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (US$/Unit) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (M Units) & (2020-2025)
Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2020-2025)
Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (US$/Unit) & (2020-2025)
Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (M Units) & (2026-2031)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (US$/Unit) & (2026-2031)
Table 27. New Sources of Growth in Benign Prostatic Hyperplasia (BPH) Drugs Application
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (M Units) & (2020-2025)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2020-2025)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2020-2025)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2024)
Table 33. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (US$/Unit) & (2020-2025)
Table 34. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Type & Application
Table 36. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 42. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 43. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 44. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 45. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 54. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 56. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 58. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 59. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 60. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 61. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 62. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2025) & (M Units)
Table 63. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2025)
Table 64. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2025)
Table 66. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2025) & (M Units)
Table 67. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2025)
Table 68. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2025) & (M Units)
Table 69. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2025)
Table 70. Eli Lilly Company Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 74. Eli Lilly Recent Development
Table 75. GlaxoSmithKline Company Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 79. GlaxoSmithKline Recent Development
Table 80. Astellas Pharma Company Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 84. Astellas Pharma Recent Development
Table 85. Sanofi Company Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 89. Sanofi Recent Development
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 94. Pfizer Recent Development
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 99. Abbott Recent Development
Table 100. Allergan Company Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 104. Allergan Recent Development
Table 105. TEVA Company Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 109. TEVA Recent Development
Table 110. Mylan Company Information
Table 111. Mylan Description and Business Overview
Table 112. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 114. Mylan Recent Development
Table 115. Novartis Company Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 119. Novartis Recent Development
Table 120. Merck Company Information
Table 121. Merck Description and Business Overview
Table 122. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 124. Merck Recent Development
Table 125. Production Base and Market Concentration Rate of Raw Material
Table 126. Key Suppliers of Raw Materials
Table 127. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 128. Benign Prostatic Hyperplasia (BPH) Drugs Customers List
Table 129. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 130. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 131. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 132. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2024 & 2031
Figure 4. Alpha-Blocker Product Picture
Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2024 & 2031
Figure 9. Hospitals Examples
Figure 10. Drugstores Examples
Figure 11. Others Examples
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2020-2031) & (US$ Million)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trends Growth Rate (2020-2031) & (US$/Unit)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 17. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region: 2020 VS 2024
Figure 19. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 20. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 23. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. China Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 25. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) Growth Rate (2020-2031)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2020-2025)
Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2026-2031)
Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2026-2031)
Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2020-2025)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate by Application in 2020 & 2024
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2026-2031)
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2026-2031)
Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2024)
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2024)
Figure 36. Global 5 Largest Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in Benign Prostatic Hyperplasia (BPH) Drugs: 2020 & 2024
Figure 37. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 38. Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 39. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 40. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
Figure 41. Channels of Distribution (Direct Vs Distribution)
Figure 42. Distributors Profiles
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232